ArticleInfectious diseases of poverty2025
Post-COVID-19 resurgence of scabies' cases in the Lazio Region, Italy: a new emerging public health threat?
Article in Infectious diseases of poverty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The rising burden of scabies in Italy: insights from a nationwide survey of dermatologists.Tropical medicine and health · 2026Article
- Scabies outbreak management in a vulnerable elderly population: Evidence from northeastern Iran.Parasite epidemiology and control · 2026Article
- Clinical characteristics associated with severe misdiagnosis of scabies: a retrospective hospital-based study.BMC infectious diseases · 2026Article
- A LAMP-based assay for rapid detection of human scabies using clinical skin scraping specimens.Scientific reports · 2026Article
- The Impact of Disease-Related Fear and Internalized Stigma on Quality of Life in Patients with Scabies: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Skin of Color in Pediatric Dermatology: A Cross-Sectional Retrospective Analysis Addressing Inclusive Diagnosis and Care.Life (Basel, Switzerland) · 2026Article
- Post-COVID-19 resurgence of scabies in Campania, Italy: the hidden burden and challenges in surveillance.Dermatology reports · 2026Article
- Ectoparasite- and Vector-Borne-Related Dermatoses: A Single-Centre Study with Practical Diagnostic and Management Insights in a One Health Perspective.Journal of clinical medicine · 2026Article
- Clinical presentation of scabies from 1996 to 2022: a retrospective cohort study from Finland.Scandinavian journal of primary health care · 2025Article
- Rising scabies incidence in Spain: a retrospective observational analysis of four national data sources, 2011 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Observational
- Tracing the Itch: A Spatiotemporal Analysis of Scabies Rates and Its Risk Factors Using the Global Burden of Disease 2021 Data.Tropical medicine & international health : TM & IH · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Scabies represents a global health issue and in 2017 was added to the World Health Organization's list of neglected tropical diseases. In European and Middle Eastern countries, cases are sporadic while recent surveillance data have pointed out an increasing incidence among vulnerable populations. Regional cases for Lazio, Italy, reported from 2017 to 2023 to the national infectious disease surveillance system were analyzed. In Lazio, just after the coronavirus disease 2019 (COVID-19) pandemic onset, a significant and immediate reduction in the incidence of scabies was recorded (- 79.6%) followed by a progressive and relevant increase (143.4% from 2020 to 2021, 142.3% from 2021 to 2022 and 170.3% from 2022 to 2023). Consistently, the number of scabies outbreaks, after a decrease following the first COVID-19 wave, has progressively increased over time, mainly due to the occurrence of outbreaks in long term facilities (750% from 2020 to 2023). The increased incidence may also be driven by the "pseudo-resistance" phenomenon (under dosed/early-discontinued treatment, suboptimal adherence, reduced drug bioavailability), but also by reduced in-vitro susceptibility to the mainly used scabicides. The rapidly evolving epidemiology of scabies in our country, as documented also in other regions, calls for a comprehensive approach to effectively address the problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.